Nifty
:
25330.25
Sensex
:
82693.71
91.15 (0.36%)
313.02 (0.38%)
Nifty
Sensex
:
:
25330.25
82693.71
91.15 (0.36%)
313.02 (0.38%)

Zydus Lifesciences Ltd.

Pharmaceuticals & Drugs - Global

Rating :
69/99

BSE: 532321 | NSE: ZYDUSLIFE

NSE BSE
1033.80
17-Sep-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1035
  •  1038.95
  •  1030
  •  1034.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  754208
  •  780064398.8
  •  1111.9
  •  795

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,04,130.12
  • 22.77
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,04,342.82
  • 1.06%
  • 4.09

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.99%
  • 0.56%
  • 5.46%
  • FII
  • DII
  • Others
  • 7.13%
  • 10.89%
  • 0.97%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.44
  • 10.04
  • 10.48

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.46
  • 15.28
  • 14.05

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.98
  • 15.71
  • 33.68

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 23.01
  • 23.72
  • 23.44

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.78
  • 3.74
  • 3.93

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.85
  • 15.10
  • 14.98

Earnings Forecasts:

(Updated: 16-09-2025)
Description
2024
2025
2026
2027
Adj EPS
44.97
44.52
41.92
46.09
P/E Ratio
22.99
23.22
24.66
22.43
Revenue
22573.8
25417
26653.9
28202.5
EBITDA
6895.1
6820.51
6483.23
6841.25
Net Income
4525.5
4514.54
4248.96
4596.99
ROA
13.61
11.77
10
9.97
P/B Ratio
4.34
3.76
3.34
2.99
ROE
20.67
17.22
14.3
13.56
FCFF
5157.1
1862.82
3872.63
3997.72
FCFF Yield
5.04
1.82
3.78
3.9
Net Debt
-4594.7
-2894.82
-5732.89
-6058.37
BVPS
238.05
275.12
309.48
345.99

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Net Sales
6,573.70
6,207.50
5.90%
6,527.90
5,533.80
17.96%
5,269.10
4,505.20
16.96%
5,237.00
4,368.80
19.87%
Expenses
4,542.30
4,123.50
10.16%
4,402.40
3,908.60
12.63%
3,881.50
3,402.80
14.07%
3,821.00
3,304.90
15.62%
EBITDA
2,031.40
2,084.00
-2.52%
2,125.50
1,625.20
30.78%
1,387.60
1,102.40
25.87%
1,416.00
1,063.90
33.10%
EBIDTM
30.90%
33.57%
32.56%
29.37%
26.33%
24.47%
27.04%
24.35%
Other Income
212.00
63.20
235.44%
80.60
161.70
-50.15%
57.50
37.70
52.52%
113.60
136.20
-16.59%
Interest
84.70
32.20
163.04%
76.60
34.60
121.39%
32.00
19.80
61.62%
25.10
8.70
188.51%
Depreciation
238.10
215.30
10.59%
237.90
205.30
15.88%
229.00
194.80
17.56%
233.60
184.20
26.82%
PBT
1,920.60
1,899.70
1.10%
1,672.00
1,547.00
8.08%
1,184.10
925.50
27.94%
1,270.90
1,007.20
26.18%
Tax
434.00
436.10
-0.48%
423.20
321.20
31.76%
179.50
213.80
-16.04%
373.10
226.40
64.80%
PAT
1,486.60
1,463.60
1.57%
1,248.80
1,225.80
1.88%
1,004.60
711.70
41.15%
897.80
780.80
14.98%
PATM
22.61%
23.58%
19.13%
22.15%
19.07%
15.80%
17.14%
17.87%
EPS
14.58
14.11
3.33%
11.64
11.75
-0.94%
10.17
7.80
30.38%
9.06
7.91
14.54%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
23,607.70
23,241.50
19,547.40
17,237.40
15,109.90
14,403.50
14,253.10
13,165.60
11,954.50
9,376.50
9,426.80
Net Sales Growth
14.52%
18.90%
13.40%
14.08%
4.90%
1.06%
8.26%
10.13%
27.49%
-0.53%
 
Cost Of Goods Sold
6,541.40
5,345.40
5,260.10
5,335.70
4,757.00
4,094.20
4,243.30
4,141.30
3,656.90
3,065.00
2,673.20
Gross Profit
17,066.30
17,896.10
14,287.30
11,901.70
10,352.90
10,309.30
10,009.80
9,024.30
8,297.60
6,311.50
6,753.60
GP Margin
72.29%
77.00%
73.09%
69.05%
68.52%
71.57%
70.23%
68.54%
69.41%
67.31%
71.64%
Total Expenditure
16,647.20
16,348.00
14,248.40
13,665.50
11,935.20
11,018.20
11,472.90
10,187.20
9,125.90
7,475.00
7,097.30
Power & Fuel Cost
-
358.20
366.30
343.50
299.30
231.60
252.90
231.60
211.40
174.50
155.40
% Of Sales
-
1.54%
1.87%
1.99%
1.98%
1.61%
1.77%
1.76%
1.77%
1.86%
1.65%
Employee Cost
-
3,289.70
2,789.00
2,456.40
2,177.70
2,069.50
2,169.80
1,903.20
1,644.70
1,485.20
1,119.00
% Of Sales
-
14.15%
14.27%
14.25%
14.41%
14.37%
15.22%
14.46%
13.76%
15.84%
11.87%
Manufacturing Exp.
-
3,445.60
2,758.10
2,639.80
2,272.30
2,271.40
2,230.00
1,923.20
1,680.40
955.30
1,397.60
% Of Sales
-
14.83%
14.11%
15.31%
15.04%
15.77%
15.65%
14.61%
14.06%
10.19%
14.83%
General & Admin Exp.
-
933.50
625.00
620.30
506.70
444.00
582.60
583.40
398.70
466.00
356.40
% Of Sales
-
4.02%
3.20%
3.60%
3.35%
3.08%
4.09%
4.43%
3.34%
4.97%
3.78%
Selling & Distn. Exp.
-
2,362.20
1,800.10
1,674.60
1,373.30
1,358.60
1,468.40
1,033.30
1,129.40
826.40
979.60
% Of Sales
-
10.16%
9.21%
9.71%
9.09%
9.43%
10.30%
7.85%
9.45%
8.81%
10.39%
Miscellaneous Exp.
-
613.40
649.80
595.20
548.90
548.90
525.90
371.20
404.40
502.60
979.60
% Of Sales
-
2.64%
3.32%
3.45%
3.63%
3.81%
3.69%
2.82%
3.38%
5.36%
4.41%
EBITDA
6,960.50
6,893.50
5,299.00
3,571.90
3,174.70
3,385.30
2,780.20
2,978.40
2,828.60
1,901.50
2,329.50
EBITDA Margin
29.48%
29.66%
27.11%
20.72%
21.01%
23.50%
19.51%
22.62%
23.66%
20.28%
24.71%
Other Income
463.70
459.60
369.40
474.60
390.70
47.40
117.10
208.50
133.00
147.10
116.60
Interest
218.40
191.00
81.20
129.90
127.00
158.80
341.80
195.80
110.80
63.10
52.80
Depreciation
938.60
915.80
764.10
722.70
713.00
669.60
696.50
598.60
538.80
373.30
292.10
PBT
6,047.60
6,246.30
4,823.10
3,193.90
2,725.40
2,604.30
1,859.00
2,392.50
2,312.00
1,612.20
2,101.20
Tax
1,409.80
1,411.90
977.50
587.80
511.70
193.60
319.80
530.30
564.40
128.90
177.40
Tax Rate
23.31%
23.43%
20.33%
22.70%
18.03%
8.07%
21.39%
22.26%
24.41%
8.00%
8.45%
PAT
4,637.80
4,467.70
3,718.10
1,870.30
2,195.40
2,154.20
1,147.80
1,801.90
1,713.00
1,453.90
1,890.90
PAT before Minority Interest
4,499.10
4,614.80
3,831.40
2,001.90
2,326.40
2,205.60
1,175.60
1,851.80
1,747.60
1,483.00
1,921.30
Minority Interest
-138.70
-147.10
-113.30
-131.60
-131.00
-51.40
-27.80
-49.90
-34.60
-29.10
-30.40
PAT Margin
19.65%
19.22%
19.02%
10.85%
14.53%
14.96%
8.05%
13.69%
14.33%
15.51%
20.06%
PAT Growth
10.90%
20.16%
98.80%
-14.81%
1.91%
87.68%
-36.30%
5.19%
17.82%
-23.11%
 
EPS
46.09
44.40
36.95
18.59
21.82
21.41
11.41
17.91
17.02
14.45
18.79

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
23,953.10
19,829.50
17,515.80
16,999.60
12,992.30
10,375.70
10,386.30
8,744.50
6,960.00
5,699.20
Share Capital
100.60
100.60
101.20
102.40
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
23,852.50
19,728.90
17,414.60
16,897.20
12,889.90
10,273.30
10,283.90
8,642.10
6,857.60
5,596.80
Non-Current Liabilities
-542.10
193.10
-725.00
-193.60
19.40
2,853.90
3,491.10
2,122.20
1,903.30
736.10
Secured Loans
0.00
0.00
0.00
0.00
0.00
1,953.60
2,332.80
200.60
319.60
393.80
Unsecured Loans
0.00
0.00
0.00
362.10
609.50
1,261.00
1,616.90
2,354.50
2,148.80
502.60
Long Term Provisions
383.90
309.70
271.80
325.00
309.50
235.20
184.10
155.90
151.20
120.70
Current Liabilities
9,041.60
5,339.70
5,526.70
7,826.80
7,861.30
8,269.40
7,342.50
6,083.00
5,305.80
3,461.00
Trade Payables
2,305.80
2,126.70
2,125.00
2,137.80
2,205.90
2,044.30
1,922.60
1,888.40
1,547.90
1,308.10
Other Current Liabilities
2,499.20
1,677.60
1,798.50
1,967.50
2,166.20
2,126.30
2,033.60
1,484.90
1,212.10
860.70
Short Term Borrowings
3,169.50
768.60
1,081.00
3,314.10
3,070.90
3,826.50
3,196.90
2,557.50
2,476.90
1,210.90
Short Term Provisions
1,067.10
766.80
522.20
407.40
418.30
272.30
189.40
152.20
68.90
81.30
Total Liabilities
34,857.90
27,634.40
24,490.00
26,687.00
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
Net Block
13,133.70
12,368.50
11,520.90
12,188.50
12,132.80
12,230.50
12,163.70
6,482.60
5,755.10
3,747.90
Gross Block
21,699.80
19,919.80
18,343.80
17,650.90
17,345.00
16,781.50
15,702.30
9,349.10
8,102.90
5,767.30
Accumulated Depreciation
8,566.10
7,551.30
6,822.90
5,462.40
5,212.20
4,551.00
3,538.60
2,866.50
2,345.80
2,016.80
Non Current Assets
17,811.80
16,135.20
14,477.60
14,438.20
14,094.30
14,118.30
14,014.70
8,911.00
8,302.90
5,751.70
Capital Work in Progress
2,691.90
2,423.30
1,200.70
725.90
783.20
741.50
837.20
1,527.20
1,543.30
950.80
Non Current Investment
1,556.70
968.00
927.30
934.80
631.20
552.20
443.60
470.90
385.70
217.10
Long Term Loans & Adv.
400.10
344.50
358.70
369.30
323.30
332.00
410.40
300.00
384.70
661.20
Other Non Current Assets
29.40
30.90
470.00
219.70
223.80
262.10
159.80
130.30
234.10
174.70
Current Assets
17,046.10
11,419.80
10,008.20
12,095.20
8,716.00
8,715.40
8,498.10
8,229.70
6,022.30
4,280.40
Current Investments
4,851.10
252.50
619.30
2,353.20
198.90
212.80
229.90
274.80
49.10
199.10
Inventories
3,944.00
3,441.90
3,413.30
3,719.40
3,236.20
2,789.00
2,688.00
2,385.30
1,803.70
1,337.10
Sundry Debtors
4,024.70
5,220.20
4,416.80
3,340.30
3,127.30
3,663.20
3,950.80
3,206.30
2,277.50
1,746.60
Cash & Bank
2,956.80
1,105.10
573.10
1,106.90
888.30
964.90
548.90
1,314.90
1,543.50
638.70
Other Current Assets
1,269.50
664.20
274.00
229.90
1,265.30
1,085.50
1,080.50
1,048.40
348.50
358.90
Short Term Loans & Adv.
717.30
735.90
711.70
1,345.50
741.40
643.90
584.50
527.70
268.50
234.80
Net Current Assets
8,004.50
6,080.10
4,481.50
4,268.40
854.70
446.00
1,155.60
2,146.70
716.50
819.40
Total Assets
34,857.90
27,555.00
24,485.80
26,533.40
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
6,776.70
3,196.30
2,688.80
2,104.50
3,293.90
2,931.50
1,281.90
919.30
1,311.70
1,893.50
PBT
6,026.70
4,838.10
2,582.70
5,232.30
2,284.80
1,495.40
2,382.10
2,312.00
1,611.90
2,098.70
Adjustment
1,020.40
546.70
933.90
-2,117.20
1,163.00
1,474.40
539.10
624.30
333.70
249.80
Changes in Working Capital
1,531.50
-902.70
-235.80
-336.00
191.10
263.80
-971.70
-1,383.90
-411.20
271.70
Cash after chg. in Working capital
8,578.60
4,482.10
3,280.80
2,779.10
3,638.90
3,233.60
1,949.50
1,552.40
1,534.40
2,620.20
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,801.90
-1,285.80
-592.00
-674.60
-345.00
-302.50
-675.40
-602.30
-237.60
-646.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.40
7.80
-30.80
14.90
-80.70
Cash From Investing Activity
-8,372.30
-1,475.20
1,535.00
-1,000.30
-724.60
-1,012.30
-4,238.70
-973.70
-2,871.90
-863.50
Net Fixed Assets
-776.80
-572.20
-669.30
-490.20
-462.80
-289.60
-1,652.30
-600.20
-557.40
-531.50
Net Investments
-4,208.50
-2,403.70
238.70
1,352.60
-66.50
-2,208.90
-577.10
305.60
-1,606.20
-108.40
Others
-3,387.00
1,500.70
1,965.60
-1,862.70
-195.30
1,486.20
-2,009.30
-679.10
-708.30
-223.60
Cash from Financing Activity
2,014.20
-1,778.80
-4,400.40
-868.30
-2,547.70
-1,528.20
1,884.60
51.50
2,315.80
-934.80
Net Cash Inflow / Outflow
418.60
-57.70
-176.60
235.90
21.60
391.00
-1,072.20
-2.90
755.60
95.20
Opening Cash & Equivalents
413.00
487.80
657.80
888.30
1,177.70
778.80
1,589.70
1,592.60
837.00
737.90
Closing Cash & Equivalent
826.80
413.00
487.80
1,106.90
1,087.20
1,177.70
778.80
1,589.70
1,592.60
837.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
238.10
197.11
173.08
166.01
126.88
101.33
101.43
85.40
67.97
55.66
ROA
14.77%
14.70%
7.82%
9.40%
9.66%
5.18%
9.34%
11.11%
12.18%
20.14%
ROE
21.08%
20.52%
11.60%
15.51%
18.88%
11.32%
19.36%
22.26%
23.43%
38.62%
ROCE
26.06%
24.90%
13.64%
15.30%
14.23%
10.02%
15.89%
18.41%
16.50%
28.60%
Fixed Asset Turnover
2.20
1.98
1.88
1.69
1.69
0.88
1.05
1.38
1.38
1.76
Receivable days
36.93
46.37
41.75
39.94
42.92
97.49
99.21
83.37
76.72
63.29
Inventory Days
29.51
32.98
38.39
42.95
38.08
70.13
70.33
63.69
59.88
54.52
Payable days
151.33
147.51
145.80
166.64
189.45
64.85
68.81
68.11
74.18
65.30
Cash Conversion Cycle
-84.89
-68.16
-65.67
-83.76
-108.45
102.77
100.73
78.94
62.42
52.51
Total Debt/Equity
0.13
0.04
0.07
0.25
0.35
0.77
0.76
0.62
0.75
0.43
Interest Cover
32.55
60.22
20.94
23.35
16.11
5.38
13.17
21.87
26.55
40.75

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Zydus Lifesciences’ arm launches first veterinary approved generic of Furosemide Tablets
    16th Sep 2025, 11:39 AM

    Manufactured under stringent quality standards, ZyVet’s Furosemide tablets are available in multiple strengths to accommodate patient-specific dosing

    Read More
  • Zydus Lifesciences’ arm launches generic of phenylpropanolamine hydrochloride tablets
    16th Sep 2025, 10:12 AM

    Phenylpropanolamine hydrochloride is commonly prescribed to treat urinary incontinence in dogs due to urethral sphincter hypotonus

    Read More
  • USFDA completes inspection at Zydus group’s injectable plant in Gujarat
    6th Sep 2025, 14:21 PM

    The inspection was conducted from August 25 to September 5, 2025 and concluded with 4 observations

    Read More
  • Zydus Lifesciences’ arm inks licensing, supply agreement with Synthon BV
    4th Sep 2025, 16:41 PM

    Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with Synthon BV of the Netherlands for Ozanimod Capsules for the United States market

    Read More
  • Zydus Lifesciences launches VaxiFlu in India
    2nd Sep 2025, 15:21 PM

    Vaxiflu - Trivalent Influenza Vaccine is recommended for individuals aged 6 months and above

    Read More
  • Zydus Lifesciences’ arm reports positive topline results from EPICS-III Phase 2(b)/3 clinical trial of Saroglitazar
    29th Aug 2025, 15:19 PM

    The company also planning to move forward with a regulatory submission to the U.S. Food and Drug Administration in the first quarter of 2026

    Read More
  • USFDA conducts inspection at Zydus group’s formulation plant in Ahmedabad
    14th Aug 2025, 12:59 PM

    The inspection concluded with NIL observations

    Read More
  • USFDA concludes inspection at Zydus Lifesciences’ formulation manufacturing plant at Baddi
    14th Aug 2025, 10:12 AM

    The inspection was conducted from August 4, 2025 to August 13, 2025

    Read More
  • Zydus Lifesciences reports 3% rise in Q1 consolidated net profit
    13th Aug 2025, 11:08 AM

    The total consolidated income of the company increased by 7.30% at Rs 6728.60 crore for Q1FY26

    Read More
  • Zydus Lifesciences - Quarterly Results
    12th Aug 2025, 13:03 PM

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Diltiazem Hydrochloride Tablets
    11th Aug 2025, 10:59 AM

    Diltiazem Hydrochloride Tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm

    Read More
  • Zydus Lifesciences gets NoC for ZDS-Varenicline Tablets 0.5 &1 mg
    7th Aug 2025, 17:53 PM

    This is the group’s first NOC approval in Canada

    Read More
  • Zydus Lifesciences’ arm completes acquisition of 85.6% equity shares of Amplitude Surgical SA
    30th Jul 2025, 10:30 AM

    Zydus MedTech France now holds 85.6% of the share capital and voting rights of the Target Entity

    Read More
  • Zydus Lifesciences gets USFDA’s tentative approval for Ibrutinib tablets
    24th Jul 2025, 16:15 PM

    The group now has 420 approvals and has so far filed around 484 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • USFDA concludes RRA at Zydus Lifesciences’ Gujarat formulations manufacturing facility
    17th Jul 2025, 10:11 AM

    At the closure, there were no observations noted, and the site was recommended for approval

    Read More
  • Zydus Lifesciences gets final nod for Celecoxib Capsules from USFDA
    16th Jul 2025, 10:11 AM

    The group now has 428 approvals and has so far filed 492 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Lifesciences’ arm incorporates wholly owned subsidiary in USA
    14th Jul 2025, 11:30 AM

    The immediate objective of incorporation of Zylidac is to acquire the target assets of Agenus

    Read More
  • USFDA concludes GMP follow-up inspection at Zydus Lifesciences’ Ahmedabad site
    19th Jun 2025, 10:08 AM

    The inspection is closed with 2 observations and none of them were related to data integrity

    Read More
  • Zydus Lifesciences gets EIR for Ankleshwar API manufacturing facility from USFDA
    12th Jun 2025, 10:12 AM

    This facility underwent an inspection from March 10, 2025 to March 14, 2025

    Read More
  • Zydus Lifesciences gets EIR for Vadodara API manufacturing facility from USFDA
    10th Jun 2025, 16:14 PM

    This facility underwent an inspection from April 21 to April 25 2025

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.